Venus Remedies rallies on launch of new cancer formulation

Posted By:

Venus Remedies rallies on launch of new cancer formulation
Shares of Venus Remedies rallied sharply today on reports of the launch of a new cancer drug. The shares of the company were up almost 5% on the National Stock Exchange.

Venus Remedies Limited has introduced for the first time a nanotechnology based "Ready to use" Single Vial Docetaxel in the domestic market under the brand name "TAXEDOLA semi-synthetic cytostatic taxane analogue, Docetaxel is considered as one of the most effective and successful oncology products, which is used mainly for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, head and neck cancer and ovarian cancer.

TAXEDOL (Docetaxel) is a single unit stable, pharmaceutical formulation which has lesser impurities in comparison to innovator product. This one vial formulation of Docetaxel will not only make the administration of the drug easier by introducing the premix solution but at the same time will provide enhanced safety to patients and para-medical staff.

Furthermore, the nano-scale size of the formulation results in improved penetration, higher efficacy, improved safety and lesser side effects.

Read more about: venus remedies
Story first published: Tuesday, July 10, 2012, 12:55 [IST]
Please Wait while comments are loading...
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'

Thousands of Goodreturn readers receive our evening newsletter.
Have you subscribed?